NASDAQ NMS - GLOBAL MARKET · KROS
+0.73% · +$0.0800 · Vol 157.5K
Market closed · last close 4:00 PM ET · price as of 16:01:35 ET
Keros Therapeutics Inc

Keros Therapeutics Inc

Biotechnology
$11.03
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
KROS
Keros Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KROS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KROS catalysts
About Keros Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
92
Country
US

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.96
Day high
$11.09
Day low
$10.80
Previous close
$10.95
52W high
$21.84
-49.50% from high
52W low
$9.91
9% of range
Market cap
$218.7M
P/E
2.48×
EPS
$-3.6000
Beta
0.66
Shares out
19.8M
Volume
157.5K
0.77× rel vol
Avg volume
203.4K
VWAP
$10.96
Price history computed in-house
1W
+5.25%
1M
+9.64%
3M
-1.78%
1Y
-29.11%
YTD
-45.83%
SMA 50 $10.67 · above
SMA 200 $13.93 · below
52W position 9%

KROS overview

Veridion Score
65
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KROS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KROS Form 4 filings
Public disclosures

Congress activity in KROS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for KROS in the cached public ledger.

Federal contracts

KROS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KROS in this window.
Lobbying spend

KROS lobbying filings, year to date.

Registered lobbying filings matched to Keros Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KROS in this window.
Loading news for KROS
Analyst ratings
Sovereign unlock shows live analyst consensus for KROS.
Options
Sovereign unlock shows live options positioning for KROS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.